Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Monopar Therapeutics stock
Learn how to easily invest in Monopar Therapeutics stock.
Monopar Therapeutics Inc is a biotechnology business based in the US. Monopar Therapeutics shares (MNPR) are listed on the NASDAQ and all prices are listed in US Dollars. Monopar Therapeutics employs 9 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Monopar Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – MNPR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Monopar Therapeutics stock price (NASDAQ: MNPR)Use our graph to track the performance of MNPR stocks over time.
Monopar Therapeutics shares at a glance
|Latest market close||$1.52|
|52-week range||$1.39 - $5.74|
|50-day moving average||$1.85|
|200-day moving average||$2.50|
|Wall St. target price||$16.80|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.77|
Buy Monopar Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Monopar Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Monopar Therapeutics price performance over time
|1 week (2022-09-23)||2.70%|
|1 month (2022-09-02)||-15.56%|
|3 months (2022-07-01)||-35.32%|
|6 months (2022-04-01)||-41.76%|
|1 year (2021-10-01)||-66.96%|
|2 years (2020-10-02)||-69.60%|
|3 years (2019-09-28)||N/A|
|5 years (2017-09-28)||N/A|
Monopar Therapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-31.44%|
|Return on equity TTM||-54.71%|
|Market capitalisation||$19.5 million|
TTM: trailing 12 months
Monopar Therapeutics share dividends
We're not expecting Monopar Therapeutics to pay a dividend over the next 12 months.
Monopar Therapeutics share price volatility
Over the last 12 months, Monopar Therapeutics's shares have ranged in value from as little as $1.391 up to $5.74. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Monopar Therapeutics's is 0.4717. This would suggest that Monopar Therapeutics's shares are less volatile than average (for this exchange).
Monopar Therapeutics overview
Monopar Therapeutics Inc. , a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
Monopar Therapeutics in the news
Monopar to Present at Roth Inaugural Healthcare Opportunities Conference
Frequently asked questionsWhat percentage of Monopar Therapeutics is owned by insiders or institutions?
Currently 64.435% of Monopar Therapeutics shares are held by insiders and 1.625% by institutions. How many people work for Monopar Therapeutics?
Latest data suggests 9 work at Monopar Therapeutics. When does the fiscal year end for Monopar Therapeutics?
Monopar Therapeutics's fiscal year ends in December. Where is Monopar Therapeutics based?
Monopar Therapeutics's address is: 1000 Skokie Boulevard, Wilmette, IL, United States, 60091 What is Monopar Therapeutics's ISIN number?
Monopar Therapeutics's international securities identification number is: US61023L1089 What is Monopar Therapeutics's CUSIP number?
Monopar Therapeutics's Committee on Uniform Securities Identification Procedures number is: 61023L108
More guides on Finder
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
Ask an Expert